Commonwealth Equity Services’s Castle Biosciences CSTL Stock Holding History

Commonwealth Equity Services’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$238K	Buy	+6,708	New	+$202K	﹤0.01%	3936
2026 Q1	–	Sell	-6,591	Closed	-$256K	–	4339
2025 Q4	$256K	Buy	+6,591	New	+$212K	﹤0.01%	3783
2023 Q4	–	Sell	-11,274	Closed	-$190K	–	3931
2023 Q3	$190K	Sell	11,274 -4,022	-26%	-$70.3K	﹤0.01%	3399
2023 Q2	$210K	Buy	+15,296	New	+$310K	﹤0.01%	3362
2022 Q2	–	Sell	-4,603	Closed	-$206K	–	3693
2022 Q1	$206K	Buy	+4,603	New	+$190K	﹤0.01%	3315
2021 Q4	–	Sell	-5,071	Closed	-$337K	–	3666
2021 Q3	$337K	Sell	5,071 -6	-0.1%	-$422	﹤0.01%	2802
2021 Q2	$372K	Buy	5,077 +1,200	+31%	+$79.3K	﹤0.01%	2717
2021 Q1	$265K	Buy	+3,877	New	+$291K	﹤0.01%	2886

Other funds holding CSTL

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Commonwealth Equity Services's CSTL Position: Q3 2026 in Review

Commonwealth Equity Services opened a new position in Castle Biosciences (CSTL) in Q3 2026: 6,708 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #3936 among its holdings. This is a return to the name: Commonwealth Equity Services previously reported a position in CSTL as recently as Q4 2025.

Commonwealth Equity Services first reported a position in CSTL in Q1 2021 and has held it in 8 quarters since. The position peaked at $372K in Q2 2021. 94 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

Commonwealth Equity Services held 6,708 shares of Castle Biosciences worth $238K as of Q3 2026.
Castle Biosciences was a new Commonwealth Equity Services position in Q3 2026.
Castle Biosciences made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q3 2026, its #3936 holding.
Commonwealth Equity Services first reported a position in Castle Biosciences in Q1 2021 and has held it in 8 quarters since.
Commonwealth Equity Services's Castle Biosciences position peaked at $372K in Q2 2021.
94 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Commonwealth Equity Services's 13F filing for Q3 2026, filed 2 Nov 2026.